SETD2 Antibody

What is SETD2 and why is it important in epigenetic research?

SETD2, also known as SET domain containing 2, belongs to the histone-lysine methyltransferase family and SET2 subfamily. This enzyme catalyzes the trimethylation of lysine 36 on histone H3 (H3K36me3), a critical epigenetic modification. SETD2 plays essential roles in chromatin structure modulation, transcription elongation via interaction with RNA polymerase II, and mediating mismatch repair . Its importance extends to DNA damage repair pathways, cell cycle regulation, and tumor suppression, making it a significant target for epigenetic and cancer research .

What applications are SETD2 antibodies validated for in research settings?

SETD2 antibodies have been validated for multiple research applications, with varying recommended dilutions:

These applications enable researchers to detect endogenous SETD2 protein expression, localization, and interaction with other proteins in various experimental contexts .

How should researchers optimize antigen retrieval for SETD2 antibody in IHC applications?

For optimal SETD2 detection in immunohistochemistry applications, researchers should implement a systematic approach to antigen retrieval. The primary recommendation is using TE buffer at pH 9.0, which effectively unmasks SETD2 epitopes in formalin-fixed, paraffin-embedded tissues. Alternatively, citrate buffer at pH 6.0 may be used if the primary retrieval method yields suboptimal results . The effectiveness of antigen retrieval is tissue-dependent, particularly with colon and esophageal cancer specimens showing robust staining after proper retrieval. Researchers should perform temperature and time optimization experiments (95-100°C for 10-30 minutes) for their specific tissue types, as retrieval conditions significantly impact signal-to-noise ratio and staining intensity for this large molecular weight protein (287-288 kDa) .

What are the recommended storage conditions for maintaining SETD2 antibody activity?

To maintain optimal SETD2 antibody activity, researchers should store commercially available antibodies at -20°C, where they typically remain stable for one year after shipment. The formulation generally contains PBS with 0.02% sodium azide and 50% glycerol at pH 7.3, which helps preserve antibody structure and function during freeze-thaw cycles . For smaller antibody volumes (20μl), products may contain 0.1% BSA as a stabilizing agent. Contrary to common practice with other antibodies, aliquoting is considered unnecessary for -20°C storage of most SETD2 antibodies, though this may vary by manufacturer . When actively using the antibody, short-term storage (1-2 weeks) at 4°C is acceptable, but repeated freeze-thaw cycles should be minimized to prevent degradation of this research-critical reagent.

How can SETD2 antibodies be employed to investigate DNA damage repair mechanisms?

SETD2 antibodies are instrumental in elucidating the protein's critical role in DNA double-strand break (DSB) repair pathways. Researchers can employ these antibodies in chromatin immunoprecipitation (ChIP) assays to analyze SETD2 recruitment to DSB sites, using 10μl of antibody with 10μg of chromatin for optimal results . Co-immunoprecipitation experiments reveal SETD2's interactions with key DNA repair proteins following damage induction. Western blot analysis of SETD2 levels, in conjunction with phosphorylated ATM, RPA, and γH2AX, provides temporal insights into repair pathway activation .

Immunofluorescence microscopy using SETD2 antibodies (1:200-1:800 dilution) alongside DNA repair markers like RAD51 and BRCA1 enables visualization of repair foci formation. This approach has demonstrated that SETD2 is necessary for ATM activation upon DNA double-strand breaks and promotes RAD51 recruitment during repair processes . For mechanistic studies, combining SETD2 antibody detection with SETD2 knockdown experiments using lentivirus-mediated shRNAs allows researchers to establish causal relationships between SETD2 function and DNA repair efficiency through direct measurement of DNA 5' end resection and homologous recombination repair capacity .

What methodological considerations are important when investigating SETD2's role in tumor suppression?

When investigating SETD2's tumor suppressor function, researchers should implement a multi-faceted experimental approach using SETD2 antibodies. First, baseline SETD2 expression should be established across normal and cancer cell lines/tissues using Western blot analysis (1:500-1:1000 dilution) and immunohistochemistry (1:50-1:500 dilution) to identify expression patterns .

Functional studies require genetic manipulation through overexpression of wildtype SETD2 or catalytically dead versions (e.g., F2478L mutant) in cancer cell lines, followed by antibody-based verification of expression levels . Functional assays should include:

Complementary SETD2 knockdown experiments using shRNAs with antibody confirmation can validate observed phenotypes through opposing effects . For in vivo studies, immunohistochemistry can assess SETD2 expression in xenograft tumor models, correlating expression with tumor growth rates, response to therapies, and patient prognosis .

How can researchers distinguish between specific and non-specific binding when using SETD2 antibodies?

Distinguishing specific from non-specific binding when using SETD2 antibodies requires a systematic validation approach. Given SETD2's large molecular weight (287-288 kDa), researchers should first confirm that the observed band in Western blot corresponds to the expected size using appropriate molecular weight markers . SETD2 knockout or knockdown controls are essential validation tools—researchers should employ SETD2-specific shRNAs or CRISPR-Cas9 gene editing to generate negative controls where the target protein is absent or substantially reduced .

Peptide competition assays provide another validation method, where pre-incubation of the antibody with its immunizing peptide should abolish specific binding. For immunofluorescence applications, co-localization studies with other H3K36me3-related proteins can confirm specific nuclear localization patterns . Additionally, cross-validating results using multiple SETD2 antibodies targeting different epitopes strengthens specificity claims. When analyzing cancer tissues, researchers should include negative (isotype control antibodies) and positive controls (tissues with known SETD2 expression) in each experimental batch to establish staining specificity .

What are the implications of SETD2 mutations for antibody-based detection in cancer research?

SETD2 mutations pose significant challenges for antibody-based detection in cancer research. These mutations can affect epitope recognition, potentially leading to false negative results if the antibody's target region is altered or deleted. Researchers investigating cancers with high SETD2 mutation rates (renal, gastric, lung cancers) should employ antibodies targeting conserved regions of the protein or use multiple antibodies recognizing different epitopes .

Immunohistochemical analysis of SETD2 in cancer tissues should be interpreted in the context of mutation status, ideally determined through parallel genomic analysis. SETD2 mutations have been linked to specific cellular pathways, including DNA damage repair, TP53, cell cycle, and NOTCH pathways . When studying immunotherapy response prediction, researchers should note that SETD2 mutant tumors may exhibit different immune infiltration profiles, with significantly higher proportions of IFN-γ, CD8+ T cells, and NK cells compared to wild-type tumors .

The detection of SETD2 dysfunction in melanoma implies poor prognosis and chemotherapy resistance, but heightened sensitivity to tyrosine kinase inhibitors (TKIs) and immunotherapy . Therefore, antibody-based SETD2 assessment may serve as a valuable biomarker for therapy selection, highlighting the importance of validation studies correlating protein expression with mutation status and treatment outcomes.

How should researchers optimize Western blot protocols for detecting the large SETD2 protein?

Optimizing Western blot protocols for detecting SETD2 (287-288 kDa) requires specific technical adaptations to accommodate its large molecular weight. Researchers should prepare low percentage (6-8%) polyacrylamide gels or gradient gels (4-15%) to facilitate efficient migration and separation of high molecular weight proteins. Extended electrophoresis time at reduced voltage (60-80V) improves resolution of large proteins. For protein transfer, researchers should implement either overnight wet transfer at low amperage (30mA) or semi-dry transfer systems specifically designed for large proteins .

Sample preparation requires careful consideration—complete lysis using RIPA buffer supplemented with protease inhibitors and mechanical disruption (sonication) helps ensure full extraction of nuclear proteins like SETD2. Protein loading should be optimized at 20-30μg per lane for cell lysates, with longer exposure times often necessary for visualization. Primary antibody incubation at 4°C overnight with gentle agitation using recommended dilutions (1:500-1:1000) followed by extended washing steps improves signal quality . High-sensitivity ECL detection systems or fluorescent secondary antibodies provide better visualization of this less abundant transcriptional regulator.

What controls should be included when performing chromatin immunoprecipitation (ChIP) with SETD2 antibodies?

When performing chromatin immunoprecipitation with SETD2 antibodies, a comprehensive set of controls is essential for result validation and interpretation. The following controls should be systematically incorporated:

For optimal ChIP results, researchers should use 10μl of SETD2 antibody with 10μg of chromatin . The fragmentation protocol should be carefully optimized to generate 200-500bp fragments, ideal for transcription factor ChIP. Quantitative PCR analysis of immunoprecipitated DNA should include normalization to input DNA and comparison to IgG control to calculate enrichment. When performing ChIP-seq experiments, additional bioinformatic quality controls such as peak distribution analysis and correlation with H3K36me3 marks provide further validation of SETD2 binding patterns .

How can researchers effectively evaluate SETD2 antibody specificity across different species?

Evaluating SETD2 antibody specificity across species requires a systematic validation approach focused on sequence homology and experimental verification. Researchers should begin with in silico analysis of epitope conservation—SETD2 shows high conservation in mammals with tested reactivity confirmed for human samples and cited reactivity for mouse models .

For cross-species validation, Western blot analysis using cell lysates from multiple species represents the primary verification method. Expected molecular weight variations should be considered; while human SETD2 appears at 287-288 kDa, slight differences may be observed in other species. Positive controls should include human cell lines with confirmed SETD2 expression (Jurkat, U2OS, K-562, HepG2) . Specificity can be further validated through siRNA knockdown experiments in cells from each species of interest, demonstrating signal reduction corresponding to decreased protein expression.

Immunoprecipitation followed by mass spectrometry provides definitive evidence of antibody specificity, confirming the identity of the captured protein across species. For immunohistochemistry applications across species, researchers should optimize antigen retrieval conditions independently for each species, as fixation effects on epitope accessibility may vary. When antibodies show cross-reactivity with orthologs in fly, canine, porcine, monkey, mouse, and rat models, validation data from each species should be documented to ensure accurate interpretation of experimental results .

What approaches can determine if SETD2 dysfunction is due to mutation versus expression changes in tumor samples?

Distinguishing between SETD2 dysfunction caused by mutations versus expression changes in tumor samples requires an integrated approach combining antibody-based protein detection with genomic and functional analyses. Researchers should implement a sequential analytical framework:

First, immunohistochemistry (1:50-1:500 dilution) and Western blot (1:500-1:1000 dilution) analyses using validated SETD2 antibodies can quantify protein expression levels in tumor versus matched normal tissues . Subsequently, genomic analysis through targeted sequencing or whole-exome sequencing should identify potential mutations, particularly focusing on the catalytic SET domain where mutations like F2478L have been shown to abolish enzymatic activity .

For functional assessment, researchers can measure H3K36me3 levels as a direct readout of SETD2 activity—reduced H3K36me3 despite normal SETD2 expression suggests mutation-induced dysfunction, while concordant reduction of both SETD2 and H3K36me3 indicates expression-based mechanisms . Cell-based functional assays comparing the effects of wild-type versus mutant SETD2 reintroduction on proliferation, colony formation, and cell cycle progression can definitively establish the functional impact of identified mutations .

This comprehensive approach has practical implications for cancer research, as SETD2 dysfunction through different mechanisms may have distinct prognostic and therapeutic implications. For instance, SETD2 dysfunction in melanoma implies poor chemotherapy response but increased sensitivity to tyrosine kinase inhibitors and immunotherapy .

How can researchers address poor signal-to-noise ratio in SETD2 immunofluorescence experiments?

Poor signal-to-noise ratio in SETD2 immunofluorescence experiments can be systematically addressed through optimization of multiple experimental parameters. First, fixation protocols significantly impact epitope availability—researchers should test both paraformaldehyde (4%, 10-15 minutes) and methanol (-20°C, 10 minutes) fixation methods, as SETD2's nuclear localization may require specific preservation approaches .

Permeabilization should be carefully optimized using varying concentrations of Triton X-100 (0.1-0.5%) or saponin to improve antibody access to nuclear targets while maintaining cellular architecture. Blocking solutions should include both serum (5-10%) matching the secondary antibody host species and BSA (1-3%) to minimize non-specific binding. Primary antibody concentration should be titrated within the recommended range (1:200-1:800) , with extended incubation (overnight at 4°C) often yielding better results for nuclear proteins.

For nuclear proteins like SETD2, adding 0.1% Tween-20 to washing buffers and extending wash durations improves background reduction. When visualizing SETD2 alongside cell cycle markers like Cyclin A, careful selection of fluorophores with minimal spectral overlap prevents bleed-through . Signal amplification systems (tyramide signal amplification or quantum dots) may be necessary for detecting low-abundance SETD2. Finally, acquiring images with confocal microscopy using appropriate positive controls (HepG2 cells) and negative controls (SETD2-depleted cells) enables accurate interpretation of nuclear staining patterns .

What strategies can overcome challenges in detecting SETD2 in formalin-fixed paraffin-embedded (FFPE) tissues?

Detecting SETD2 in formalin-fixed paraffin-embedded (FFPE) tissues presents challenges due to fixation-induced epitope masking and protein crosslinking. To overcome these obstacles, antigen retrieval optimization is paramount—while TE buffer at pH 9.0 is generally recommended, researchers should systematically compare this with citrate buffer (pH 6.0) for their specific tissue types . Heat-induced epitope retrieval using pressure cooking (125°C, 3-5 minutes) often yields superior results compared to microwave or water bath methods for nuclear proteins like SETD2.

Section thickness affects antibody penetration—5μm sections typically provide an optimal balance between structural preservation and reagent accessibility. Primary antibody incubation should be extended (overnight at 4°C) at concentrations between 1:50-1:500, with optimization for each tissue type . Signal amplification systems such as polymer-based detection or tyramide signal amplification can significantly enhance sensitivity for detecting this low-abundance protein.

Tissue-specific background reduction strategies include additional blocking steps with avidin/biotin blocking kits when using biotinylated detection systems and hydrogen peroxide treatment (3%, 10 minutes) to block endogenous peroxidase activity. Validation should include positive control tissues (human colon or esophageal cancer) known to express SETD2 and negative controls using isotype-matched antibodies . When investigating specific pathologies, comparative analysis between tumor and adjacent normal tissue within the same slide provides internal reference for expression evaluation.

What approaches can resolve inconsistent results between different SETD2 antibody clones?

Inconsistent results between different SETD2 antibody clones can stem from multiple factors including epitope differences, production methods, and application-specific performance variations. Researchers should implement a systematic resolution approach beginning with comprehensive antibody validation. This includes verifying the exact epitope location for each antibody clone—antibodies targeting different domains of the large SETD2 protein (288 kDa) may yield varying results if domain-specific post-translational modifications or protein interactions affect epitope accessibility .

Western blot analysis using positive control cell lines (Jurkat, U2OS, K-562) with all antibody clones simultaneously can establish relative detection efficiencies and confirm target specificity through consistent molecular weight observation . For definitive validation, knockdown/knockout experiments using siRNA or CRISPR-Cas9 should demonstrate signal reduction with all antibody clones. Application-specific optimization is essential—while one clone may excel in Western blotting, another might be superior for immunohistochemistry or ChIP applications .

When discrepancies persist, researchers should consider alternative detection methods such as mass spectrometry to confirm protein identity. For functional studies, complementary approaches measuring SETD2 activity through H3K36me3 levels can provide indirect validation. Collaborative cross-validation with other laboratories using standardized protocols helps establish consensus on antibody performance. Finally, consulting published literature and antibody validation databases helps identify consistently reliable antibody clones for specific applications .

How can researchers differentiate between SETD2 and other SET domain-containing proteins in experimental systems?

Differentiating between SETD2 and other SET domain-containing proteins requires strategic experimental design exploiting their distinct molecular and functional characteristics. Researchers should select antibodies targeting unique regions outside the conserved SET domain to minimize cross-reactivity—antibodies recognizing the C-terminal regions of SETD2 typically offer greater specificity . Western blot analysis provides initial differentiation based on molecular weight, as SETD2 (287-288 kDa) is substantially larger than most other SET domain proteins .

Immunoprecipitation followed by mass spectrometry provides definitive identification based on unique peptide signatures. For functional discrimination, researchers can exploit SETD2's specific role as the sole trimethylase for H3K36 in mammals—while other SET proteins may generate H3K36me1/me2, only SETD2 produces H3K36me3 . Chromatin immunoprecipitation experiments reveal distinct genomic binding patterns, with SETD2 particularly associated with actively transcribed gene bodies .

Knockdown validation experiments should demonstrate specific effects on H3K36me3 levels without affecting methylation marks generated by other SET proteins. Co-immunoprecipitation studies can identify SETD2-specific interaction partners, particularly RNA polymerase II, which distinguishes it from other SET domain proteins . When investigating cancer contexts, SETD2's specific roles in DNA damage repair and S-phase cell cycle regulation provide functional discrimination from other histone methyltransferases .

How might new antibody technologies advance our understanding of SETD2 dynamics in living cells?

Emerging antibody technologies present unprecedented opportunities for studying SETD2 dynamics in living cellular systems. Single-domain antibodies (nanobodies) derived from camelid immunoglobulins can be engineered to recognize specific SETD2 epitopes while maintaining functionality in intracellular environments. These can be fused with fluorescent proteins to create chromobodies for real-time tracking of SETD2 movements during transcription elongation and DNA repair processes .

CRISPR-based tagging systems allow endogenous SETD2 labeling with split fluorescent proteins or HaloTag/SNAP-tag technologies, enabling pulse-chase experiments to determine protein turnover rates in different cellular compartments. These approaches could resolve the dynamic recruitment of SETD2 to DNA damage sites, which current fixed-cell immunofluorescence methods can only capture as static images .

Proximity labeling techniques using SETD2 antibody-enzyme fusions (APEX2 or TurboID) would enable spatiotemporal mapping of the SETD2 interactome under various cellular conditions, potentially revealing context-specific binding partners during transcription versus DNA repair. Förster resonance energy transfer (FRET) or bimolecular fluorescence complementation (BiFC) antibody-based biosensors could visualize SETD2 conformational changes upon substrate binding or interaction with RNA polymerase II . These technologies would transform our understanding of SETD2 from static immunodetection to dynamic functional analysis in living systems, potentially revealing new therapeutic intervention points.

What are the potential applications of SETD2 antibodies in cancer diagnostics and treatment selection?

SETD2 antibodies hold significant promise for advancing cancer diagnostics and precision treatment selection. In diagnostic applications, immunohistochemical assessment of SETD2 expression and localization could serve as a prognostic biomarker, particularly in melanoma where SETD2 dysfunction correlates with poor prognosis and specific treatment response patterns . For treatment stratification, SETD2 status determination could identify patients likely to exhibit chemotherapy resistance but enhanced responsiveness to tyrosine kinase inhibitors and immunotherapy approaches .

The integration of SETD2 antibody-based tissue analysis with genomic profiling creates opportunities for comprehensive diagnostic platforms. Such integration could distinguish between dysfunctional SETD2 resulting from mutations versus expression changes, potentially guiding different therapeutic strategies . Furthermore, antibodies recognizing specific SETD2 mutations could enable rapid screening without sequencing, particularly valuable in resource-limited clinical settings.

For monitoring treatment response, sequential biopsy analysis using SETD2 antibodies could track changes in expression or localization during therapy. This approach may reveal resistance mechanisms or adaptive responses, enabling timely intervention. In experimental therapeutics, SETD2 antibody-drug conjugates represent a potential targeted approach for cancers overexpressing this protein. The correlation between SETD2 mutations and immune cell infiltration (IFN-γ, CD8+ T cells, NK cells) suggests antibody-based SETD2 assessment could identify candidates for immunotherapy, particularly in lung adenocarcinoma . These applications collectively highlight SETD2's potential as a clinically actionable biomarker for personalized cancer management.